Pharmacyclics Inc.

Partners announce PFS benefit from monotherapy head-to-head. Summit’s Phase III program outside China adds chemotherapy to the mix

Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy

Back to School 2023: An analysis of biotech takeouts by market cap size

Firm is latest top-tier EU VC to raise new fund, hitting €600M

BioCentury’s 2023 Financial Markets Preview

Led by Bob Duggan and Maky Zanganeh, small cap paying $500M up front to get U.S.-EU-Japan rights to bispecific ivonescimab

Plus Arvinas hires Northcott as CCO, Manion joins Aclaris and updates from AnHeart, Gracell, Find and more 

Newly launched K36 in-licensed potential first-in-class therapy from Novartis for multiple myeloma subset

Menin inhibitor moving toward clinic three months after series A